Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Key Inclusion Criteria * Stage II to IV (M0) CSCC, for which surgery would be recommended in routine clinical practice. For stage II patients, lesion must be ≥3 cm at the longest diameter. * At least 1 lesion that is measurable by RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ, bone marrow function, and hepatic function as defined in the protocol Key Exclusion Criteria * Solid malignancy within 5 years of the projected enrollment date, or hematologic malignancy (including chronic lymphocytic leukemia \[CLL\]) at any time * Distant metastatic disease (M1), visceral and/or distant nodal * Prior radiation therapy for CSCC * Patients with a condition requiring corticosteroid therapy (\>10 mg prednisone/day or equivalent) within 14 days of the first dose of study drug. * Patients with active, known, or suspected autoimmune disease that has required systemic therapy within 5 years of the projected enrollment date. * History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. * Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency * Active tuberculosis NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply